化工社
首页MCP工作台Skills
首页工作台通知我的
llms.txt · MCP 指南隐私政策 · 服务条款 · 支持v1.8.0
  1. 首页
  2. /反应

三氟乙酸 → n-{(1r)-1-[(4-Chlorophenyl)methyl]-2-[4-(2-{[(2-cyanophenyl)sulfonyl]amino}-phenyl)piperidyl]-2-oxoethyl}((3s)(3-1,2,3,4-tetrahydroisoquinolyl))-carboxamide

HRID 489698
笔记
打印预览

反应方程式

HRID 489698 反应方程式
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][C@@H:9]([NH:36][C:37]([C@@H:39]2[CH2:48][C:47]3[C:42](=[CH:43][CH:44]=[CH:45][CH:46]=3)[CH2:41][N:40]2C(OC(C)(C)C)=O)=[O:38])[C:10]([N:12]2[CH2:17][CH2:16][CH:15]([C:18]3[CH:23]=[CH:22][CH:21]=[CH:20][C:19]=3[NH:24][S:25]([C:28]3[CH:33]=[CH:32][CH:31]=[CH:30][C:29]=3[C:34]#[N:35])(=[O:27])=[O:26])[CH2:14][CH2:13]2)=[O:11])=[CH:4][CH:3]=1.C(O)(C(F)(F)F)=O>C(Cl)Cl>[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][C@@H:9]([NH:36][C:37]([C@@H:39]2[CH2:48][C:47]3[C:42](=[CH:43][CH:44]=[CH:45][CH:46]=3)[CH2:41][NH:40]2)=[O:38])[C:10]([N:12]2[CH2:13][CH2:14][CH:15]([C:18]3[CH:23]=[CH:22][CH:21]=[CH:20][C:19]=3[NH:24][S:25]([C:28]3[CH:33]=[CH:32][CH:31]=[CH:30][C:29]=3[C:34]#[N:35])(=[O:26])=[O:27])[CH2:16][CH2:17]2)=[O:11])=[CH:4][CH:3]=1
参与物实验过程后处理来源与证据反应笔记

参与物

4

反应物 2

HCID 6422三氟乙酸HCID 69151038Tert-butyl 3-(n-{(1r)-1-[(4-chlorophenyl)methyl]-2-[4-(2-{[(2-cyanophenyl)sulfonyl]amino}phenyl)piperidyl]-2-oxoethyl}carbamoyl)(3s)-1,2,3,4-tetrahydroisoquinoline-2-carboxylate

产物 1

HCID 10122668n-{(1r)-1-[(4-Chlorophenyl)methyl]-2-[4-(2-{[(2-cyanophenyl)sulfonyl]amino}-phenyl)piperidyl]-2-oxoethyl}((3s)(3-1,2,3,4-tetrahydroisoquinolyl))-carboxamide

试剂、催化剂与溶剂 1

HCID 6344
二氯甲烷
溶剂

实验过程

The title compound was prepared according to the procedure described in Example 3 (Step b) using tert-butyl 3-(N-{(1R)-1-[(4-chlorophenyl)methyl]-2-[4-(2-{[(2-cyanophenyl}sulfonyl]amino}phenyl)piperidyl]-2-oxoethyl]carbamoyl)(3S)-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (Step a) (167 mg, 0.21 mmol) and 50% TFA in CH2Cl2 (10 mL). Purification by reverse phase preparative HPLC [Phenomenex; 5 μm 250×21.2 mm, 5% to 95% CH3CN (0.1% TFA) in H2O (0.1% TFA) over 30 min, then 100% CH3CN (0.1% TFA) for 2 min] provided the title compound (TFA salt) as a white foam (76 mg). MS (ESI, pos. ion) m/z: 682 (M+1); (ESI, neg. ion) m/z: 680 (M−1). Calc'd for C37H36ClN5O4S: 681.22.

后处理

  1. customThe title compound was prepared
  2. customPurification by reverse phase preparative HPLC [Phenomenex

来源与证据

ORD记录
ord-38bf3b8403434c93845969ea469f29b6
来源数据集
uspto-grants-2005_12
DOI
10.6084/m9.figshare.5104873.v1
专利号
US06977264B2

反应笔记

加载中…

本页导航参与物实验过程后处理来源与证据反应笔记